Great comprehensive review of oral arguments at the federal circuit in the Myriad case by Kevin Noonan of Patent Docs.
Filed under: Gene Patents | Tagged: AMP v. USPTO, DNA patents, gene patents, Kevin Noonan, Myriad, Patent Docs |
-
Join 20 other followers
-
Recent Posts
- Translational Research Forum at BIO International Convention
- University-Industry Partnering at BIO Convention Webinar by AUTM June 16, 3-4PM
- BIO has issued a strong letter of support for the Manager’s Amendment to H.R. 1249, the America Invents Act
- Supreme Court Affirms: High Level of Proof Needed to Invalidate A Patent
- Debunking the Myth: ‘Gene Patents’ are not necessary for healthcare innovation.
Categories
- 2010 BIO International Convention
- about the blog
- Bayh-Dole
- BIO Home Videos
- Counterfeits
- economic development
- events
- Evolving IP Market Place FTC
- Follow-on Biologics
- Gene Patents
- Global Health
- Green Technology
- International
- IP Counsels' Committee
- IP News Weekly
- NIH
- Patent Reform
- patents
- Supreme Court
- Sustainability
- technology transfer
- Twitter Twang
- Uncategorized
- United States Patent and Trademark Office
- US Federal Circuit of Appeals
- WIPO
Top Clicks
- None
- brought to you by
Biotechnology Industry Organization
1201 Maryland Ave., SW
Washington, DC 20024
202.962.9200
www.bio.org
terms of use
privacy policy
-
Blogroll- An error has occurred; the feed is probably down. Try again later.
- Access and Benefit Sharing ACLU America Invents Act AMP v. USPTO AUTM backlog Barack Obama Bayh-Dole Bayh-Dole Act BIO bio09 BIO Letter to the President biotechnology Biotechnology Industry Organization Brazil business model CBD Charles Grassley China clear and convincing evidence Convention on Biological Diversity David Kappos Department of Commerce developing countries DNA patents economic development economic growth emerging markets fee diversion First inventor to file First to file Follow-on Biologics FTC FTC report gene patenting gene patents Gene Quinn global health Green Technology healthcare reform humanitarian humanitarian technologies i4i Innovation intellectual property International IP News Weekly Jim Greenwood job creation job growth Lamar Smith Leahy licensing Microsoft Microsoft v. i4i Myriad Nagoya Protocol National Institutes of Health NIH patent Patent and Trademark Office Patent Office Patent Reform PTO R&D Research and Development Stanford v. Roche Supreme Court Sustainability technology transfer United Nations United States Patent and Trademark Office United States Patent Office US Federal Circuit of Appeals USPTO
Archives
Blog at WordPress.com. WP Designer.
Patently BIOtech 
Myriad is much more than this year’s hot patent litigation (i.e., this year’s successor to Bilski). It’s critical for the courts to get this one right. I hope the Justices of the SCOTUS are already doing their research, so they’ll be proficient on the details when this case finally reaches them.